BRPI0519923A2 - polipeptìdeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-o-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-o-desacilado, vacina, e , método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo - Google Patents
polipeptìdeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-o-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-o-desacilado, vacina, e , método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativoInfo
- Publication number
- BRPI0519923A2 BRPI0519923A2 BRPI0519923-9A BRPI0519923A BRPI0519923A2 BR PI0519923 A2 BRPI0519923 A2 BR PI0519923A2 BR PI0519923 A BRPI0519923 A BR PI0519923A BR PI0519923 A2 BRPI0519923 A2 BR PI0519923A2
- Authority
- BR
- Brazil
- Prior art keywords
- lps
- gram
- negative
- bacterium
- deacylated
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 241000588807 Bordetella Species 0.000 title abstract 2
- 108020004414 DNA Proteins 0.000 title abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 239000002158 endotoxin Substances 0.000 abstract 9
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 9
- 230000000694 effects Effects 0.000 abstract 2
- 201000005702 Pertussis Diseases 0.000 abstract 1
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 244000000058 gram-negative pathogen Species 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
POLIPEPTìDEO, SEQüêNCIA DE DNA, VETOR DE DNA, ANTICORPO, BACTéRIA, MéTODO PARA PRODUZIR LPS PARCIALMENTE 3-O-DESACILADO, COMPOSIçãO, USOS DA BACTERIA, E DE LPS DE BORDETELLA ISOLADO COMPREENDENDO LPS PELO MENOS PARCIALMENTE 3-O-DESACILADO, VACINA, E, MéTODO IN VITRO PARA A DESACILAçãO DE LPS GRAM-NEGATIVO OU DE COMPOSIçõES COMPREENDENDO LPS GRAM-NEGATIVO. A presente invenção proporciona novos polipeptídeos Gram- negativos exibindo atividade de lipídeo A 3-O-desacilase e que são capazes de modificar e/ou desintoxicar LPS Gram-negativos. A presente invenção também proporciona bactérias Gram-negativas, lipopolissacarídeos (LPS) de bactérias Gram-negativas e composições compreendendo LPS, que são proporcionadas com ou tratadas com uma atividade de 3-O-desacilase de acordo com a invenção e que podem ser utilizadas para propósitos farmacêuticos e/ou veterinários, em particular para a preparação de vacinas acelulares ou de célula inteira contra patógenos Gram-negativos tais como Bordeteila pertuss is, Bordeteila parapertuss is, e Bordetelia bronchiseptica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04078445 | 2004-12-17 | ||
| PCT/NL2005/050081 WO2006065139A2 (en) | 2004-12-17 | 2005-12-16 | Deacylation of lps in gram negative bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0519923A2 true BRPI0519923A2 (pt) | 2009-08-11 |
| BRPI0519923A8 BRPI0519923A8 (pt) | 2018-01-23 |
Family
ID=34928754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519923A BRPI0519923A8 (pt) | 2004-12-17 | 2005-12-16 | polipeptídeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-0-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-0-desacilado, vacina, e, método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo, e, para induzir uma resposta imune contra bordetella. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8048433B2 (pt) |
| EP (1) | EP1828378B1 (pt) |
| JP (1) | JP5378685B2 (pt) |
| CN (1) | CN101203605B (pt) |
| AU (1) | AU2005317304B2 (pt) |
| BR (1) | BRPI0519923A8 (pt) |
| CA (1) | CA2590906C (pt) |
| DK (1) | DK1828378T3 (pt) |
| ES (1) | ES2493440T3 (pt) |
| MX (1) | MX2007007288A (pt) |
| NO (1) | NO340331B1 (pt) |
| NZ (1) | NZ555889A (pt) |
| PL (1) | PL1828378T3 (pt) |
| PT (1) | PT1828378E (pt) |
| WO (1) | WO2006065139A2 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9296995B2 (en) * | 2007-03-26 | 2016-03-29 | De Staat Der Nederlanden, Vert. Door De Minister Van Vws | Vaccines against Bordetella pertussis based on LPS glycosyltransferase mutants |
| WO2014024026A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Method for eliciting in infants an immune response against rsv and b. pertussis |
| US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
| US11052142B2 (en) | 2013-06-04 | 2021-07-06 | Petr G. Aparin | Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants) |
| KR102125600B1 (ko) | 2013-06-04 | 2020-06-23 | 페트르 젠나디에비치 아파린 | 개질된 내독성 세균 지질다당류(변형체), 개질된 지질다당류들(변형체들)의 조합물, 및 이를 함유한 백신(변형체) 및 약제 조성물(변형체) |
| KR20160040290A (ko) | 2013-08-05 | 2016-04-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 조합 면역원성 조성물 |
| US10420833B2 (en) | 2014-05-19 | 2019-09-24 | Board Of Regents, The University Of Texas System | Combinatorial platform for the display of surface adjuvants and antigens |
| CN104388368B (zh) * | 2014-10-30 | 2017-02-15 | 四川农业大学 | 一株低内毒素大肠杆菌原核表达工程菌突变株及构建方法 |
| JP7031933B2 (ja) * | 2016-01-28 | 2022-03-08 | イントラヴァック ビー．ブイ． | 改変されたテトラアシル化ナイセリアｌｐｓ |
| CN105567620B (zh) * | 2016-01-29 | 2019-03-19 | 江南大学 | 一株产减毒类脂A的Cronobacter sakazakii突变株及其应用 |
| CN105695540A (zh) * | 2016-03-18 | 2016-06-22 | 辽宁成大生物股份有限公司 | 一种革兰氏阴性菌胞壁抗原的制备方法 |
| CN110461865A (zh) * | 2017-03-13 | 2019-11-15 | 由卫生福利和体育大臣代表的荷兰王国 | 包含具有降低的反应原性的lps的博德特氏菌疫苗 |
| US11744884B2 (en) * | 2017-05-15 | 2023-09-05 | University Of Maryland, Baltimore | Live Salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof |
| AU2018379236B2 (en) * | 2017-12-04 | 2025-02-27 | Intravacc B.V. | An improved process for producing outer membrane vesicles |
| US20230183656A1 (en) * | 2020-05-14 | 2023-06-15 | Merck Patent Gmbh | Methods and compositions for purifying adeno associated virus particles or adenoviruses |
| US20250263447A1 (en) | 2020-09-04 | 2025-08-21 | Intravacc B.V. | Ompa mutations enhance omv production in bordetella pertussis |
| EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH650681A5 (en) | 1981-08-14 | 1985-08-15 | Dso Pharmachim | Whooping cough vaccine |
| WO1989001976A1 (en) * | 1987-09-04 | 1989-03-09 | Amgen Inc. | Recombinant dna-derived bordetella toxin subunit analogs |
| EP0484621A3 (en) * | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
| DE69333467T2 (de) * | 1992-08-18 | 2005-01-20 | Dimminaco Ag | Bordetella bronchiseptica impfstoff |
| CA2433502A1 (en) * | 1995-05-04 | 1996-11-07 | Aventis Pasteur Limited | Acellular pertussis vaccines and methods of preparation thereof |
| US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
| PL190237B1 (pl) * | 1997-04-01 | 2005-11-30 | Corixa Corp | Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie |
| CA2264970A1 (en) * | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
| US6482807B1 (en) * | 1998-11-03 | 2002-11-19 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | LPS with reduced toxicity from genetically modified gram negative bacteria |
| US6531131B1 (en) * | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
| AU2002307448A1 (en) * | 2001-04-20 | 2002-11-05 | President And Fellows Of Harvard College | Methods and compositions for the modulation of biofilm formation |
-
2005
- 2005-12-16 US US11/722,034 patent/US8048433B2/en not_active Expired - Fee Related
- 2005-12-16 CN CN200580048420.6A patent/CN101203605B/zh not_active Expired - Fee Related
- 2005-12-16 BR BRPI0519923A patent/BRPI0519923A8/pt not_active Application Discontinuation
- 2005-12-16 JP JP2007546589A patent/JP5378685B2/ja not_active Expired - Fee Related
- 2005-12-16 PL PL05815467T patent/PL1828378T3/pl unknown
- 2005-12-16 EP EP05815467.5A patent/EP1828378B1/en not_active Expired - Lifetime
- 2005-12-16 DK DK05815467.5T patent/DK1828378T3/da active
- 2005-12-16 AU AU2005317304A patent/AU2005317304B2/en not_active Ceased
- 2005-12-16 WO PCT/NL2005/050081 patent/WO2006065139A2/en not_active Ceased
- 2005-12-16 CA CA2590906A patent/CA2590906C/en not_active Expired - Fee Related
- 2005-12-16 ES ES05815467.5T patent/ES2493440T3/es not_active Expired - Lifetime
- 2005-12-16 MX MX2007007288A patent/MX2007007288A/es active IP Right Grant
- 2005-12-16 PT PT58154675T patent/PT1828378E/pt unknown
- 2005-12-16 NZ NZ555889A patent/NZ555889A/en not_active IP Right Cessation
-
2007
- 2007-06-18 NO NO20073088A patent/NO340331B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2590906C (en) | 2017-01-03 |
| WO2006065139A2 (en) | 2006-06-22 |
| JP5378685B2 (ja) | 2013-12-25 |
| EP1828378A2 (en) | 2007-09-05 |
| BRPI0519923A8 (pt) | 2018-01-23 |
| US8048433B2 (en) | 2011-11-01 |
| PT1828378E (pt) | 2014-10-10 |
| CN101203605B (zh) | 2016-01-27 |
| CA2590906A1 (en) | 2006-06-22 |
| EP1828378B1 (en) | 2014-06-11 |
| NO340331B1 (no) | 2017-04-03 |
| DK1828378T3 (da) | 2014-09-01 |
| MX2007007288A (es) | 2008-02-25 |
| NO20073088L (no) | 2007-09-17 |
| US20080274145A1 (en) | 2008-11-06 |
| JP2008523805A (ja) | 2008-07-10 |
| ES2493440T3 (es) | 2014-09-11 |
| CN101203605A (zh) | 2008-06-18 |
| NZ555889A (en) | 2009-07-31 |
| WO2006065139A3 (en) | 2006-10-19 |
| AU2005317304B2 (en) | 2011-06-23 |
| AU2005317304A1 (en) | 2006-06-22 |
| PL1828378T3 (pl) | 2014-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0519923A2 (pt) | polipeptìdeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-o-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-o-desacilado, vacina, e , método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo | |
| BRPI0411505A (pt) | uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa | |
| BR0210225A (pt) | Holotoxina do cólera imunogênica mutante, composição imunogênica, método para realçar a resposta imune de um hospedeiro vertebrado a um antìgeno, sequência de dna isolada e purificada, molécula de ácido nucleico, célula hospedeira, método para produzir uma holotoxina do cólera imunogênica mutante, e, uso de uma holotoxina do cólera mutante | |
| BR112022013753A2 (pt) | Composição sintética de micróbios funcionalmente otimizados, e, método | |
| Williams et al. | Catecholate receptor proteins in Salmonella enterica: role in virulence and implications for vaccine development | |
| WO2009104074A3 (en) | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells | |
| BRPI0620946A8 (pt) | anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica | |
| ATE522541T1 (de) | Bakterielle adhäsine konformere | |
| BRPI0802049A2 (pt) | composiÇço cosmÉtica ou dermatolàgica, usos de pelo menos um meio de cultura celular, processo cosmÉtico para melhorar a homeostase cutÂnea e processo para preparar uma composiÇço cosmÉtica ou dermatolàgica | |
| BRPI0409789B8 (pt) | célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva | |
| BRPI0408085A (pt) | composição e método para o tratamento e prevenção de infecções entéricas bacterianas | |
| ES2096262T3 (es) | Nuevas cyclosporins modificadas en la posicion 1. | |
| PE20061107A1 (es) | Composiciones de tigeciclina y metodos para su preparacion | |
| Gibbons et al. | Vitamin K compounds in bacteria that are obligate anaerobes | |
| BR112022024128A2 (pt) | Composição de microbiota vaginal, e, método para tratar uma infecção | |
| AR033574A1 (es) | Una cepa bacteriana del grupo de las bacterias lacticas capaces de reducir la tendencia de un individuo a desarrollar reacciones alergicas, las composiciones alimenticias y farmaceuticas que la contienen y las vacunas que la contienen | |
| Walter et al. | Moderate effect of enamel matrix derivative (Emdogain® Gel) on Porphyromonas gingivalis growth in vitro | |
| BRPI0609692C1 (pt) | processos de fermentação e de fabricação de uma preparação de um antígeno de c. diphtheriae | |
| ATE544471T1 (de) | Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen | |
| Yoshimura et al. | Proteome analysis of Porphyromonas gingivalis cells placed in a subcutaneous chamber of mice | |
| BRPI0518080A (pt) | bactéria transformada ou uma progênie da mesma, método para transformar uma bactéria, mycobacterium transformada ou uma progênie da mesma e vacina compreendendo uma mycobacterium transformada ou uma progênie da mesma | |
| AU2017203173B2 (en) | Method For The Production Of Protein Complexes And Vaccine Compositions Comprising The Same | |
| BR0215124A (pt) | Compostos e seus usos, composições farmacêutica e cosmética e uso cosmético de uma composição cosmética | |
| ATE435864T1 (de) | Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2- aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln | |
| BRPI0409023A (pt) | meio da cultura, método para preparar o citado meio, coleta e clonagem de células tronco, água micro-agregada, composição e método para prepará-la |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
| B25A | Requested transfer of rights approved |
Owner name: DE STAAT DER NEDERLANDEN, VERTEGENWOORDIGD DOOR DE Free format text: TRANSFERIDO DE: NVI NEDERLANDS VACCININSTITUUT |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09R | Decision of refusal: republication [chapter 9.2.3 patent gazette] |
Free format text: REPUBLICACAO POR TER SIDO CONSTATADO ERRO MATERIAL. |
|
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |